Research & Studies
Share your love
Phase 3 Trial for AZR-MD-001 in MGD Patients Begins
Azura Ophthalmics has reached a significant milestone with the enrollment of the first patient in the ASTRO study—a phase 3 clinical trial evaluating the efficacy and safety of AZR-MD-001 in patients grappling with clinical signs and symptoms of meibomian gland…
Novel Eyeglass Lens Tech Offers Relief for Migraine Patients
This spring, individuals grappling with migraines find relieve with a novel solution for managing light sensitivity, thanks to new eyeglass lens technology developed by a physician-scientist at the University of Utah John A. Moran Eye Center. The Impact of Migraine…
Fairer AI in ophthalmology via implicit fairness learning for mitigating sexism and ageism – Nature
Fairer AI in ophthalmology via implicit fairness learning for mitigating sexism and ageism Nature Source: Author: | Date: 2024-06-04 07:00:00 Source: Author: | Date: 2024-06-04 07:00:00
Funding Boost for LambdaVision’s Artificial Retina
LambdaVision, a pioneering company dedicated to developing a protein-based artificial retina aimed at restoring sight lost to retinal degenerative diseases, announced the successful first closing of its seed round to advance its artificial retina development. The funding injection will fuel…
Quantel Medical Launches POCKET III
Quantel Medical, a division of Lumibird Medical, has unveiled its latest innovation with the launch of the POCKET III handheld pachymeter. This compact device, according to Quantel, sets a new standard as the lightest connected handheld pachymeter on the market,…
Zeiss Introduces Upgraded Cirrus 6000 OCT
Zeiss Medical Technology has introduced a series of enhancements to the Cirrus 6000, promising a more streamlined and data-centric workflow for ophthalmologists. This update boasts the largest OCT reference database in the US market and fortified cybersecurity features. With recent…
AAO’s Tool for Enhanced IOL Cataract Surgery
The U.S. Food and Drug Administration (FDA) has qualified the Assessment of IntraOcular Lens Implant Symptoms (AIOLIS), developed by the American Academy of Ophthalmology (AAO), as a Medical Device Development Tool (MDDT). This designation empowers medical device sponsors to employ…
IND for DF-003 Cleared by FDA for ROSAH Syndrome Trial
In a significant development for the medical community, Drug Farm announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application of DF-003. This novel drug, hailed as a first-in-class oral medication,…
European Authorization Granted for Lytenava in Wet AMD
Outlook Therapeutics has achieved a significant milestone with the European Commission granting Marketing Authorization for Lytenava (bevacizumab gamma), an innovative ophthalmic formulation designed for the treatment of wet AMD (Age-related Macular Degeneration). This approval marks a pivotal moment as Lytenava…
Opthea Completes Enrollment in Wet AMD Phase 3 Trials
Opthea Limited announced the completion of enrollment in both the COAST and ShORe trials, constituting its pivotal Phase 3 clinical program. This program is designed to assess the safety and superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A therapies…